| Literature DB >> 34901461 |
Mei Peng1, Ling Yu1, Yali Deng1, Wen Zhong1, Yanting Nie1, Wen Deng1, Jian Huang1, Yiling Ding1.
Abstract
In this study, a treatment method was assessed for the prevention and treatment of postpartum bleeding after combined surgery in patients having late pregnancy with the complication of acute Stanford type A aortic dissection. The clinical records of ten patients receiving treatment at the Second Xiangya Hospital of Central South University between March 2012 and March 2021 were retrospectively analysed. All patients were diagnosed with acute Stanford type A aortic dissection according to computed tomography angiography of the thoracic and abdominal aorta. Aortic valve function was assessed using two-dimensional echocardiography. All patients experienced uterine-incision delivery under systemic anaesthesia. During the operation, intrauterine Bakri balloon tamponade and cervical cerclage were performed. Postpartum bleeding was effectively controlled for all patients. The extracorporeal circulation time was 230-295 min, the postpartum 24 h bleeding volume was 500-870 mL, the volume of physiological saline injected into the balloon was 290-515 mL, and the intrauterine balloon compression time was 28-51 h. No postpartum bleeding occurred. A 42-days follow-up showed no late postpartum bleeding, poor uterine incision healing, or puerperal infection, and no uterine removal was performed. Intrauterine Bakri balloon tamponade plus cervical cerclage can effectively prevent intra- and postoperative postpartum bleeding in pregnant patients with aortic dissection.Entities:
Keywords: Bakri balloon; Stanford type A aortic dissection; cervical cerclage; intrauterine tamponade; postpartum bleeding; pregnancy
Year: 2021 PMID: 34901461 PMCID: PMC8627917 DOI: 10.1515/med-2021-0392
Source DB: PubMed Journal: Open Med (Wars)
General data of ten pregnant patients with acute type A aortic dissection
| Patient no. | Age | Pregnancy and childbirth times | Gestational weeks | Fundamental disease | D-dimer (μg/L) | BMI | Diagnostic method | Primary symptom |
|---|---|---|---|---|---|---|---|---|
| 1 | 43 | G2P1A1 | 28+5 | Diabetes + antiphospholipid syndrome | 4.53 | 24 | CTA + TEE | Poststernal pain + upper abdominal pain + subxiphoid pain, complicated with dyspnoea, vomiting, and amaurosis |
| 2 | 39 | G5P1A3 | 31 | Marfan’s syndrome | 2.58 | 23 | CTA + TTE | Poststernal pain |
| 3 | 26 | G1P0A0 | 32+4 | Marfan’s syndrome | 3.56 | 25 | CTA + TTE | Chest pain + chest distress |
| 4 | 29 | G3P1A1 | 34 | Marfan’s syndrome | 3.49 | 23 | CTA + TTE | Upper abdominal pain |
| 5 | 30 | G2P1A0 | 32+1 | Chronic hypertension | 4.23 | 22 | CTA | Chest and back pain, vomiting, and blurred vision |
| 6 | 32 | G4P1A2 | 36+3 | Pregnancy-induced hypertension | 3.02 | 26 | CTA + TEE | Chest and subxiphoid pain |
| 7 | 35 | G2P0A1 | 37+1 | Pregnancy-induced hypertension | 2.49 | 24 | CTA + TEE | Middle and upper abdominal pain + back pain |
| 8 | 36 | G3P1A1 | 37+4 | None | 3.06 | 21 | CTA | Chest and back pain |
| 9 | 38 | G4P1A3 | 33 | Pregnancy-induced hypertension | 4.21 | 22 | CTA + TTE | Chest pain + dyspnoea |
| 10 | 22 | G4P3A0 | 33+1 | Marfan’s syndrome | 3.12 | 22 | CTA + TTE | Persistent tearing pain in chest and back |
Figure 1Bakri balloon.
Blood loss and the volume of physiological saline injected into the intrauterine balloon within 24 h after caesarean section
| Index | No. 1 | No. 2 | No. 3 | No. 4 | No. 5 | No. 6 | No. 7 | No. 8 | No. 9 | No. 10 |
|---|---|---|---|---|---|---|---|---|---|---|
| Extracorporeal circulation time (min) | 232 | 230 | 271 | 248 | 257 | 226 | 241 | 295 | 274 | 261 |
| Blood loss during caesarean section (within 1 h of operation)/physiological saline volume injected into the balloon (mL) | 150/170 | 200/200 | 250/220 | 180/160 | 200/200 | 300/200 | 200/200 | 280/230 | 200/180 | 200/200 |
| Blood loss within 1–2 h of delivery/physiological saline volume newly injected into the balloon (mL) | 50/20 | 40/25 | 60/35 | 50/30 | 60/20 | 40/20 | 70/30 | 80/50 | 70/30 | 50/20 |
| Blood loss within 2–4 h of delivery/physiological saline volume newly injected into the balloon (mL) | 60/25 | 50/20 | 60/35 | 50/20 | 40/20 | 50/30 | 60/30 | 100/60 | 80/40 | 50/20 |
| Blood loss within 4–6 h of delivery/physiological saline volume newly injected into the balloon (mL) | 80/35 | 70/40 | 80/50 | 100/60 | 100/60 | 120/80 | 90/45 | 180/65 | 100/60 | 60/25 |
| Blood loss within 6–8 h of delivery/physiological saline volume newly injected into the balloon (mL) | 50/20 | 50/10 | 50/30 | 50/20 | 50/10 | 50/40 | 50/30 | 50/30 | 50/30 | 30/15 |
| Blood loss within 8–10 h of delivery/physiological saline volume newly injected into the balloon (mL) | 40/10 | 50/5 | 50/30 | 50/20 | 50/5 | 50/40 | 50/25 | 50/25 | 50/25 | 40/15 |
| Blood loss within 10–12 h of delivery/physiological saline volume newly injected into the balloon (mL) | 30/5 | 40/5 | 40/25 | 40/15 | 40/5 | 40/30 | 40/20 | 40/20 | 40/20 | 30/15 |
| Blood loss within 12–14 h of delivery/physiological saline volume newly injected into the balloon (mL) | 20/5 | 30/5 | 30/15 | 30/15 | 30/5 | 30/25 | 30/15 | 30/15 | 30/15 | 20/10 |
| Blood loss within 14–16 h of delivery/physiological saline volume newly injected into the balloon (mL) | 10/0 | 30/5 | 30/15 | 30/10 | 30/5 | 30/25 | 30/10 | 30/10 | 30/15 | 20/10 |
| Blood loss within 16–20 h of delivery/physiological saline volume newly injected into the balloon (mL) | 10/0 | 20/0 | 20/10 | 20/5 | 10/0 | 20/10 | 20/10 | 20/10 | 20/10 | 10/0 |
| Blood loss within 20–24 h of delivery/physiological saline volume newly injected into the balloon (mL) | 0/0 | < 10/0 | 10/5 | < 10/0 | < 10/0 | < 10/0 | < 10/0 | < 10/0 | < 10/0 | 10/0 |
| Total blood loss within 24 h of delivery/total physiological saline volume in the balloon (mL) | 500/290 | 590/315 | 680/470 | 600/350 | 610/330 | 740/500 | 650/415 | 870/515 | 630/425 | 520/330 |
| Balloon placement time (h) | 28 | 31 | 32 | 40 | 42 | 47 | 40 | 51 | 48 | 38 |